Recruiting PHASE2 INTERVENTIONAL 5-arm NCT06787612

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Multi-arm Phase 2 Study of Ubamatamab (REGN4018; MUC16×CD3 Bispecific Antibody) With or Without Additional Agents in Platinum-Resistant Ovarian Cancer

Sponsor: Regeneron Pharmaceuticals

Conditions Ovarian Cancer

Interventions Bevacizumab Cemiplimab Fianlimab PLD Sarilumab Ubamatamab

Updated 9 times since 2025 Last updated: Feb 17, 2026 Started: May 28, 2025 Primary completion: Dec 7, 2028 Completion: Dec 7, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Ovarian Cancer, this trial is actively recruiting participants. The trial is conducted by Regeneron Pharmaceuticals and has accumulated 9 data snapshots since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

9 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE2
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE2
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE2
Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE2
Oct 2025 — Nov 2025 [monthly]

Recruiting PHASE2

▶ Show 4 earlier versions

Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE2
Jul 2025 — Sep 2025 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jun 2025 — Jul 2025 [monthly]

Not Yet Recruiting PHASE2
Feb 2025 — Jun 2025 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Regeneron Pharmaceuticals

Data source: Regeneron Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adana, Turkey (Türkiye) , Altındağ, Turkey (Türkiye) , Ankara, Turkey (Türkiye) , Birmingham, United States , Boston, United States , Changhua, Taiwan , Chicago, United States , Daegu, South Korea , Detroit, United States , Gaziantep, Turkey (Türkiye) and 22 more locations